Abstract:Key Points Parkinson's disease is a progressive neurological disorder characterized primarily by motor symptoms that include rigidity, hypokinesia and tremor. The most pronounced neuropathological feature is a loss of dopaminergic neurons in the substantia nigra pars compacta, which leads to a reduction in dopamine levels in the target region, the striatum. In the substantia nigra, some neurons have intracytoplasmic inclusions known as Lewy bodies. In most patients, Parkinson's disease shows no clear inheritance and the cause of neurodegeneration is not known. Several disease mechanisms have been proposed, including oxidative stress and mitochondrial dysfunction. Some emphasis has been placed on the possibility that environmental toxins trigger these pathological changes. In the late 1990s, the discovery of the gene that causes a rare autosomal-dominant form of Parkinson's disease led to renewed interest in the search for pathogenic mechanisms. The mutated gene encodes α-synuclein, a synaptic protein of unknown function. It has been suggested that it plays a role in the recycling of vesicles that have released their neurotransmitter content into the synaptic cleft. Moreover, further rare forms of Parkinson's disease have been identified that result from mutations in parkin and ubiquitin carboxy-terminal hydrolase L1. These proteins participate in the ubiquitin–proteasome pathway, which is responsible for the degradation of unwanted proteins. We speculate why changes in these diverse genes lead to a neurodegenerative process that is relatively focused on dopamine-containing neurons, and emphasize the role of dopamine-dependent oxidative stress in this process. We believe that there are multiple aetiological triggers, resulting from either genetic changes or environmental insults, which share the same final common pathway to cell death in dopaminergic neurons. Increased levels of cytoplasmic dopamine in nigral neurons in Parkinson's disease patients might result in dopamine oxidation and the generation of reactive oxygen species that can damage and eventually kill these neurons. One pathway that might lead to these events involves impaired vesicular storage of dopamine. Recent experimental evidence shows that the expression of mutant α-synuclein in a human dopaminergic cell line increases cytoplasmic dopamine levels and raises the levels of superoxide radicals in the cytoplasm. Dopamine-induced oxidative stress, impaired synaptic vesicle function and misfolding of α-synuclein, due to mutations or to oxidative damage to this protein, might be components in a self-perpetuating vicious cycle that eventually leads to the demise of dopaminergic neurons.

Dysfunction Of Two Lysosome Degradation Pathways Of Alpha-Synuclein In Parkinson'S Disease: Potential Therapeutic Targets?

Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson’s disease: potential therapeutic targets?

Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies

Structure, Distribution, and Genetic Profile of Α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.

alpha-synuclein, autophagy-lysosomal pathway, and Lewy bodies: mutations, propagation, aggregation, and the formation of inclusions

In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons

The Role of α-synuclein and Autophagy in Parkinson's disease

From Pathogenesis to Therapeutic Prospects

The role of polo-like kinases 2 in the proteasomal and lysosomal degradation of alpha-synuclein in neurons

Dysfunction of Proteasome and Formation of Lewy Body in Sporadic Parkinson's Disease

Alpha-Synuclein: The Interplay Of Pathology, Neuroinflammation, And Environmental Factors In Parkinson'S Disease

Role of Α-Synuclein in Microglia: Autophagy and Phagocytosis Balance Neuroinflammation in Parkinson’s Disease

Alpha-Synuclein Aggregation in Parkinson's Disease

Contribution of Autophagy-Lysosomal Pathway in the Exosomal Secretion of Alpha-Synuclein and Its Impact in the Progression of Parkinson’s Disease

Initiation and propagation of α-synuclein aggregation in the nervous system

Alteration of dynein function affects α-synuclein degradation via the autophagosome-lysosome pathway.

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein

α-Synuclein at the Presynaptic Axon Terminal as a Double-Edged Sword

Role of microglial activation induced by α-synuclein in pathogenesis of Parkinson's disease

Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein

Α-Synuclein Induces Deficiency in Clathrin-Mediated Endocytosis Through Inhibiting Synaptojanin1 Expression